M 3 antagonist activity was assessed in electrically stimulated human bronchial strips; potency, onset and offset of action of aclidinium, tiotropium and ipratropium were determined. M 2 antagonist activity was assessed in electrically stimulated isolated human left atria; duration of action was calculated.
INTRODUCTION
Muscarinic antagonists, such as aclidinium, tiotropium and ipratropium, are known to exert their bronchodilator effects by blocking the actions of acetylcholine at M 3 receptors on airway smooth muscle [1, 2] . However, interactions with muscarinic receptors outside expressed by cardiac myocytes [3] [4] [5] [6] , induces tachycardia, considered the most severe side effect associated with muscarinic antagonist use [7] . Here, we report the functional potency and duration of action of aclidinium bromide at M 2 and M 3 muscarinic receptors in isolated cardiac and airway tissues of human origin compared with tiotropium and ipratropium.
METHODS
Human lung tissue was harvested from patients undergoing surgery for lung carcinoma and left atrial tissue from patients undergoing cardiac bypass surgery. None of the patients had a history of asthma. The protocol for the use of lung or cardiac tissues was approved by the Ethics Committee of University Clinic Hospital (Valencia, Spain), and informed consent was obtained from all patients.
Fresh bronchial strips were mounted in a superfusion chamber containing oxygenated Kreb's solution (KHS) at 37°C [8, 9] . Spontaneous tone was inhibited by zileuton 10 lM and fexofenadine 10 lM [10] . Electrical stimulation at 8 Hz, over 0.5 ms and 40-50 V was delivered as 10 s trains of square-wave pulses The rates of onset (t 1/2 ) and duration of action (offset) of the antagonists were defined as the time taken from antagonist addition to 50% inhibition of tone, and from antagonist washout to recover 50% (t 1/2 ) [8] or maximal recovery (t max ) of the maximum carbachol-induced relaxation, respectively. The concentration of antagonist required for 50% inhibition of the electrically stimulated contraction (IC 50 ) and the offset (t 1/2 ) was calculated using nonlinear regression analysis.
Statistical significance, set at the 0.05 level, was determined by parametric analysis of variance, using two-sided statistical tests, followed by Bonferroni's multiple comparison test. All data analyses were performed using GraphPad Prism (San Diego, CA, USA).
RESULTS
Aclidinium, ipratropium and tiotropium produced concentration-dependent relaxation in isolated human bronchial rings. All three muscarinic antagonists inhibited the contractile response induced by electrical stimulation with similar potency, as expressed by IC 50 values (Table 1 ).
The duration of action (offset time; at a concentration that inhibited 75% of the electrically stimulated contraction) of aclidinium at the M 3 receptor was significantly longer than that of ipratropium (Table 1; P\0.05), whereas no recovery of tone was observed after washout of tiotropium for the duration of the study. The onset of action of aclidinium was similar to that of ipratropium and significantly faster than tiotropium (Table 1 ; P\0.05).
The duration of action of aclidinium at the M 2 receptor was significantly longer than that of ipratropium and shorter than that of tiotropium (Table 1 ; both P\0.05); aclidinium inhibited the bradycardic effect of carbachol with a longer duration of action compared with ipratropium, but shorter than tiotropium (Table 1) . Aclidinium had a shorter duration of action at the M 2 receptor than at the M 3 receptor (Table 1) .
DISCUSSION
Our results demonstrate that in human bronchial tissue, aclidinium had a similar potency at M 3 receptors to that of tiotropium Offset time (t 1/2 ) defined as the time from antagonist washout to achieve 50% recovery of tone and ipratropium, although its onset of action was significantly faster than tiotropium and its duration of action was significantly longer than ipratropium. These results are consistent with previous preclinical studies in isolated guinea pig trachea [11, 12] . The faster onset of action of aclidinium compared with tiotropium and the long duration of action of both are consistent with the clinical profile of these compounds [13] .
In human left atrial tissue, aclidinium had a shorter duration of action at M 2 receptors than tiotropium, but longer than ipratropium. These results are also consistent with those previously described in isolated guinea pig left atria and in membranes expressing human M 2 receptors [11, 12] . 
CONCLUSION
These results, together with the high plasma hydrolysis rate of aclidinium in comparison with tiotropium [14] , may translate into a reduced propensity for systemic effects, particularly unwanted cardiovascular adverse events in the clinical setting, and there is increasing evidence to support this hypothesis [15] [16] [17] . 
